21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013

Benjamin M. Parsons, Jeffrey Landercasper, Angela L. Smith, Ronald S. Go, Andrew J. Borgert, Leah L. Dietrich

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The purpose of this study was to determine if receipt of chemotherapy was associated with utilization of the 21-gene recurrence score assay (RS assay) or with recurrence score (RS) in eligible patients. Using the National Cancer Data Base (NCDB), we identified female patients eligible for RS assay based on National Comprehensive Cancer Network (NCCN) guidelines: age 18–70, ER-positive and HER2-negative early-stage breast cancer diagnosed during 2010–2013. We excluded patients not meeting testing guidelines. Inclusion required result of RS in patients who underwent RS assay and status for receipt of chemotherapy. Multivariable logistic regression models and propensity matched analysis were used to determine associations between RS assay and RS with receipt of chemotherapy. Among 129,765 patients who were eligible, 74,778 underwent RS assay and had results available. Of these, 59.5 % (44,505) had low-risk, 32.0 % (23,920) had intermediate-risk, and 8.5 % (6353) had high-risk RS. Patients with intermediate- and high-risk RS were more likely to receive chemotherapy [OR 12.9 (CI 12.2–13.6), p <0.001 and OR 87.2 (CI 79.6–95.6), p <0.0001], respectively. In both low- and intermediate-risk groups, increasing RS score was significantly associated with increasing odds of receiving chemotherapy [OR 1.10 (CI 1.09–1.12), p <0.0001 and OR 1.26 (CI 1.25–1.27), p <0.0001, respectively, for each point increase in RS]. Receipt of chemotherapy was more likely in patients who did not undergo RS assay compared to those who did, OR 1.21 (CI 1.175–1.249) p <0.0001. The utilization of RS assay and the RS were both strongly associated with chemotherapy receipt. Patients eligible for chemotherapy, based on NCCN criteria, were more likely to receive chemotherapy if they did not undergo RS assay or they had a high RS.

Original languageEnglish (US)
Pages (from-to)315-326
Number of pages12
JournalBreast Cancer Research and Treatment
Volume159
Issue number2
DOIs
StatePublished - Sep 1 2016

Fingerprint

Databases
Breast Neoplasms
Recurrence
Drug Therapy
Genes
Neoplasms
Logistic Models
Guidelines

Keywords

  • 21-Gene RS
  • Adjuvant chemotherapy
  • Breast cancer
  • NCDB
  • Oncotype Dx

ASJC Scopus subject areas

  • Medicine(all)
  • Oncology
  • Cancer Research

Cite this

21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer : an analysis of the NCDB 2010–2013. / Parsons, Benjamin M.; Landercasper, Jeffrey; Smith, Angela L.; Go, Ronald S.; Borgert, Andrew J.; Dietrich, Leah L.

In: Breast Cancer Research and Treatment, Vol. 159, No. 2, 01.09.2016, p. 315-326.

Research output: Contribution to journalArticle

Parsons, Benjamin M. ; Landercasper, Jeffrey ; Smith, Angela L. ; Go, Ronald S. ; Borgert, Andrew J. ; Dietrich, Leah L. / 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer : an analysis of the NCDB 2010–2013. In: Breast Cancer Research and Treatment. 2016 ; Vol. 159, No. 2. pp. 315-326.
@article{98f982f261c44f9f95e756a8315bbad3,
title = "21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer: an analysis of the NCDB 2010–2013",
abstract = "The purpose of this study was to determine if receipt of chemotherapy was associated with utilization of the 21-gene recurrence score assay (RS assay) or with recurrence score (RS) in eligible patients. Using the National Cancer Data Base (NCDB), we identified female patients eligible for RS assay based on National Comprehensive Cancer Network (NCCN) guidelines: age 18–70, ER-positive and HER2-negative early-stage breast cancer diagnosed during 2010–2013. We excluded patients not meeting testing guidelines. Inclusion required result of RS in patients who underwent RS assay and status for receipt of chemotherapy. Multivariable logistic regression models and propensity matched analysis were used to determine associations between RS assay and RS with receipt of chemotherapy. Among 129,765 patients who were eligible, 74,778 underwent RS assay and had results available. Of these, 59.5 {\%} (44,505) had low-risk, 32.0 {\%} (23,920) had intermediate-risk, and 8.5 {\%} (6353) had high-risk RS. Patients with intermediate- and high-risk RS were more likely to receive chemotherapy [OR 12.9 (CI 12.2–13.6), p <0.001 and OR 87.2 (CI 79.6–95.6), p <0.0001], respectively. In both low- and intermediate-risk groups, increasing RS score was significantly associated with increasing odds of receiving chemotherapy [OR 1.10 (CI 1.09–1.12), p <0.0001 and OR 1.26 (CI 1.25–1.27), p <0.0001, respectively, for each point increase in RS]. Receipt of chemotherapy was more likely in patients who did not undergo RS assay compared to those who did, OR 1.21 (CI 1.175–1.249) p <0.0001. The utilization of RS assay and the RS were both strongly associated with chemotherapy receipt. Patients eligible for chemotherapy, based on NCCN criteria, were more likely to receive chemotherapy if they did not undergo RS assay or they had a high RS.",
keywords = "21-Gene RS, Adjuvant chemotherapy, Breast cancer, NCDB, Oncotype Dx",
author = "Parsons, {Benjamin M.} and Jeffrey Landercasper and Smith, {Angela L.} and Go, {Ronald S.} and Borgert, {Andrew J.} and Dietrich, {Leah L.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1007/s10549-016-3926-5",
language = "English (US)",
volume = "159",
pages = "315--326",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - 21-Gene recurrence score decreases receipt of chemotherapy in ER+ early-stage breast cancer

T2 - an analysis of the NCDB 2010–2013

AU - Parsons, Benjamin M.

AU - Landercasper, Jeffrey

AU - Smith, Angela L.

AU - Go, Ronald S.

AU - Borgert, Andrew J.

AU - Dietrich, Leah L.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - The purpose of this study was to determine if receipt of chemotherapy was associated with utilization of the 21-gene recurrence score assay (RS assay) or with recurrence score (RS) in eligible patients. Using the National Cancer Data Base (NCDB), we identified female patients eligible for RS assay based on National Comprehensive Cancer Network (NCCN) guidelines: age 18–70, ER-positive and HER2-negative early-stage breast cancer diagnosed during 2010–2013. We excluded patients not meeting testing guidelines. Inclusion required result of RS in patients who underwent RS assay and status for receipt of chemotherapy. Multivariable logistic regression models and propensity matched analysis were used to determine associations between RS assay and RS with receipt of chemotherapy. Among 129,765 patients who were eligible, 74,778 underwent RS assay and had results available. Of these, 59.5 % (44,505) had low-risk, 32.0 % (23,920) had intermediate-risk, and 8.5 % (6353) had high-risk RS. Patients with intermediate- and high-risk RS were more likely to receive chemotherapy [OR 12.9 (CI 12.2–13.6), p <0.001 and OR 87.2 (CI 79.6–95.6), p <0.0001], respectively. In both low- and intermediate-risk groups, increasing RS score was significantly associated with increasing odds of receiving chemotherapy [OR 1.10 (CI 1.09–1.12), p <0.0001 and OR 1.26 (CI 1.25–1.27), p <0.0001, respectively, for each point increase in RS]. Receipt of chemotherapy was more likely in patients who did not undergo RS assay compared to those who did, OR 1.21 (CI 1.175–1.249) p <0.0001. The utilization of RS assay and the RS were both strongly associated with chemotherapy receipt. Patients eligible for chemotherapy, based on NCCN criteria, were more likely to receive chemotherapy if they did not undergo RS assay or they had a high RS.

AB - The purpose of this study was to determine if receipt of chemotherapy was associated with utilization of the 21-gene recurrence score assay (RS assay) or with recurrence score (RS) in eligible patients. Using the National Cancer Data Base (NCDB), we identified female patients eligible for RS assay based on National Comprehensive Cancer Network (NCCN) guidelines: age 18–70, ER-positive and HER2-negative early-stage breast cancer diagnosed during 2010–2013. We excluded patients not meeting testing guidelines. Inclusion required result of RS in patients who underwent RS assay and status for receipt of chemotherapy. Multivariable logistic regression models and propensity matched analysis were used to determine associations between RS assay and RS with receipt of chemotherapy. Among 129,765 patients who were eligible, 74,778 underwent RS assay and had results available. Of these, 59.5 % (44,505) had low-risk, 32.0 % (23,920) had intermediate-risk, and 8.5 % (6353) had high-risk RS. Patients with intermediate- and high-risk RS were more likely to receive chemotherapy [OR 12.9 (CI 12.2–13.6), p <0.001 and OR 87.2 (CI 79.6–95.6), p <0.0001], respectively. In both low- and intermediate-risk groups, increasing RS score was significantly associated with increasing odds of receiving chemotherapy [OR 1.10 (CI 1.09–1.12), p <0.0001 and OR 1.26 (CI 1.25–1.27), p <0.0001, respectively, for each point increase in RS]. Receipt of chemotherapy was more likely in patients who did not undergo RS assay compared to those who did, OR 1.21 (CI 1.175–1.249) p <0.0001. The utilization of RS assay and the RS were both strongly associated with chemotherapy receipt. Patients eligible for chemotherapy, based on NCCN criteria, were more likely to receive chemotherapy if they did not undergo RS assay or they had a high RS.

KW - 21-Gene RS

KW - Adjuvant chemotherapy

KW - Breast cancer

KW - NCDB

KW - Oncotype Dx

UR - http://www.scopus.com/inward/record.url?scp=84981288369&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981288369&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-3926-5

DO - 10.1007/s10549-016-3926-5

M3 - Article

C2 - 27507245

AN - SCOPUS:84981288369

VL - 159

SP - 315

EP - 326

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -